Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



SINO BIOPHARMACEUTICAL LIMITED 中國生物製藥有限公司

(Incorporated in the Cayman Islands with limited liability) Website: www.sinobiopharm.com (Stock code: 1177)

POLL RESULTS OF EXTRAORDINARY GENERAL MEETING HELD ON 15 JULY 2020

The Board is pleased to announce that all the Resolutions as set out in the EGM Notice were duly passed by the Shareholders by way of poll at the EGM held on 15 July 2020.

References are made to the notice (the "EGM Notice") of the extraordinary general meeting (the "EGM") of Sino Biopharmaceutical Limited (the "Company") dated 24 June 2020 and the circular (the "Circular") of the Company dated 24 June 2020. Unless otherwise defined, terms used herein shall have the same meanings as defined in the Circular.

The poll results in respect of the resolutions (the "**Resolutions**") proposed at the EGM held on 15 July 2020 are as follows:

Ordinary Resolutions		Number of votes (%)	
		For	Against
1	To approve the bonus issue of shares on the basis of one bonus share for every two existing issued shares in the share capital of the Company	8,515,846,443 (100.00%)	0 (0.00%)
2	To approve the increase in the authorised share capital of the Company from HK\$500,000,000.00 divided into the 20,000,000,000 shares to HK\$750,000,000.00 divided into 30,000,000,000 shares	8,495,730,324 (99.76%)	20,109,119 (0.24%)

As more than 50% of the votes were cast in favour of the Resolutions, all the Resolutions were duly passed as ordinary resolutions of the Company at the EGM.

As at the date of the EGM, the issued share capital of the Company comprised 12,581,751,487 Shares, which was the total number of Shares entitling the Shareholders to attend and vote on all the Resolutions proposed at the EGM. No Shareholder was required to attend and vote only against the Resolutions at the EGM. No Shareholder was required to abstain from voting on the Resolutions at the EGM, and there were no Shares entitling the Shareholders to attend and abstain from voting at the EGM as set out in Rule 13.40 of the Listing Rules.

The Company's branch share registrar and transfer office in Hong Kong, Tricor Tengis Limited, was appointed as the scrutineer of the vote-taking at the EGM.

By order of the Board Sino Biopharmaceutical Limited Tse, Theresa Y Y Chairwoman

Hong Kong, 15 July 2020

As at the date of this announcement, the Board of the Company comprises eight Executive Directors, namely Ms. Tse, Theresa Y Y, Mr. Tse Ping, Ms. Cheng Cheung Ling, Mr. Tse, Eric S Y, Mr. Tse Hsin, Mr. Wang Shanchun, Mr. Tian Zhoushan and Ms. Li Mingqin and four Independent Non-Executive Directors, namely Mr. Lu Zhengfei, Mr. Li Dakui, Ms. Lu Hong and Mr. Zhang Lu Fu.